Urinary DKK3 as a biomarker for short-term kidney function decline in children with chronic kidney disease: an observational cohort study

Childhood-onset chronic kidney disease is a progressive condition that can have a major effect on life expectancy and quality. We evaluated the usefulness of the kidney tubular cell stress marker urinary Dickkopf-related protein 3 (DKK3) in determining the short-term risk of chronic kidney disease p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet child & adolescent health 2023-06, Vol.7 (6), p.405-414
Hauptverfasser: Speer, Thimoteus, Schunk, Stefan J, Sarakpi, Tamim, Schmit, David, Wagner, Martina, Arnold, Ludger, Zewinger, Stephen, Azukaitis, Karolis, Bayazit, Aysun, Obrycki, Lukasz, Kaplan Bulut, Ipek, Duzova, Ali, Doyon, Anke, Ranchin, Bruno, Caliskan, Salim, Harambat, Jerome, Yilmaz, Alev, Alpay, Harika, Lugani, Francesca, Balat, Ayse, Arbeiter, Klaus, Longo, Germana, Melk, Anette, Querfeld, Uwe, Wühl, Elke, Mehls, Otto, Fliser, Danilo, Schaefer, Franz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Childhood-onset chronic kidney disease is a progressive condition that can have a major effect on life expectancy and quality. We evaluated the usefulness of the kidney tubular cell stress marker urinary Dickkopf-related protein 3 (DKK3) in determining the short-term risk of chronic kidney disease progression in children and identifying those who will benefit from specific nephroprotective interventions. In this observational cohort study, we assessed the association between urinary DKK3 and the combined kidney endpoint (ie, the composite of 50% reduction of the estimated glomerular filtration rate [eGFR] or progression to end-stage kidney disease) or the risk of kidney replacement therapy (ie, dialysis or transplantation), and the interaction of the combined kidney endpoint with intensified blood pressure reduction in the randomised controlled ESCAPE trial. Moreover, urinary DKK3 and eGFR were quantified in children aged 3–18 years with chronic kidney disease and urine samples available enrolled in the prospective multicentre ESCAPE (NCT00221845; derivation cohort) and 4C (NCT01046448; validation cohort) studies at baseline and at 6-monthly follow-up visits. Analyses were adjusted for age, sex, hypertension, systolic blood pressure SD score (SDS), BMI SDS, albuminuria, and eGFR. 659 children were included in the analysis (231 from ESCAPE and 428 from 4C), with 1173 half-year blocks in ESCAPE and 2762 in 4C. In both cohorts, urinary DKK3 above the median (ie, >1689 pg/mg creatinine) was associated with significantly greater 6-month eGFR decline than with urinary DKK3 at or below the median (–5·6% [95% CI –8·6 to –2·7] vs 1·0% [–1·9 to 3·9], p
ISSN:2352-4642
2352-4650
DOI:10.1016/S2352-4642(23)00049-4